Trial Profile
The Effects of Omalizumab on the Late-phase Response to Nasal Allergen Challenge
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2015
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma; Nephritis; Urticaria
- Focus Pharmacodynamics
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Nov 2009 New trial record